Rein Therapeutics (RNTX)

• Market cap: $37.6M
• 1 day: -9.09%
• 5 days: -4.41%
• 1 month: 21.5%
• 3 months: -16.13%
• 6 months: 2.36%
• Year to date: 4%
• 1 year: -34.34%
• 5 years: -96.56%
• 10 years: -99.4%
• Sector: Healthcare
• Industry: Biotechnology

About: Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Employees: 11